Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA

Omeros said the EMA’s CHMP issued a negative opinion on its marketing authorization application for narsoplimab to treat transplant-associated thrombotic microangiopathy (TA-TMA). The decision followed re-examination of the CHMP’s original negative opinion, adopted in June 2026; the provided article text contains no further details.

Analysis

The re-examination result weakens the near-term European approval case for narsoplimab and removes an important potential catalyst; it does not, on the information provided, establish the drug’s prospects in other jurisdictions or the ultimate European Commission outcome. The investment impact therefore turns on two items not supplied: the CHMP’s specific objections and how much value Omeros assigns to European TA-TMA sales relative to its other assets and available cash. Without those, do not translate the opinion into a precise revenue or valuation haircut.

Near term, expect OMER to trade more on the perceived probability of a viable regulatory path than on current product economics. Over the next 1–3 months, the key catalysts are publication of the full assessment, Omeros’ response, and clarification of the formal EU decision and any resubmission or appeal route. Over 6–18 months, the larger risk is whether continued development or regulatory work consumes cash without a credible approval path; verify runway and funding needs before sizing exposure. The negative signal is meaningful, but a short may be crowded or already reflected in the share price. A clear, addressable deficiency and credible path to resolution would weaken the bearish thesis; an unrebutted efficacy or safety concern, or a materially shortened cash runway, would strengthen it.

Key Decisions for Investors

• Maintain a cautious, underweight bias in OMER rather than initiating an unhedged short solely on this announcement. Reassess after the full CHMP rationale and the stock’s post-news price action are available.
• Treat any European sales contribution as at risk in valuation scenarios until the regulatory path is clearer; do not assume the opinion determines narsoplimab’s status outside Europe.
• Set a near-term alert for the complete CHMP assessment, formal European Commission action, and Omeros’ stated next steps. A credible remediation or resubmission plan is the principal event that could reverse the negative read-through.
• Before increasing exposure, verify cash runway, expected regulatory and development spending, and the company’s dependence on this program. A shortened runway or financing need would amplify downside; evidence of adequate runway and a viable alternative path would limit it.